Research programme: somatropin mimetics - Celera Genomics/Pfizer
Alternative Names: Growth hormone mimetics research programme - Celera Genomics/Pfizer; Somatropin mimetics research programme - Celera Genomics/PfizerLatest Information Update: 19 Jan 2005
At a glance
- Originator Celera Genomics Group; Pfizer
- Class
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Growth disorders
Most Recent Events
- 19 Jan 2005 No development reported - Preclinical for Growth disorders in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group